Product Name: RSK2 (711-724)
Product Number: PE-01AQN85
Size: 1 mg      Price:72.00
5 mg      $US156.00
20 mg      276.00
Peptide Name: RSK2 (711-724)

Product Use: Services as a blocking peptide for use with the RSK2-PCT rabbit polyclonal antibody (Cat. No.: AB-NK165-3) that is also available from Kinexus. The peptide sequence is located in the pre-C-terminus.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: CNRNQSPVLEPVGRS

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 1655.79 Da

Peptide Purity Percent after Synthesis and Purification: >80

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: RSK2 pan-specific antibody (Cat. No.: AB-NK165-3)

Scientific Background: RSK2 (RPSKA3) is one of several protein kinases that can phosphorylate KinSub1RRDSV. RSK2 is a protein-serine/threonine kinase of the AGC group and RSK family, and is a member of the RSK (ribosomal S6 kinase) family of growth factor-regulated kinases. It is moderate to highly expressed in most tested human tissues. RSK proteins have two kinase catalytic domains and are phosphorylated by MAPK proteins in response to growth factors, polypeptide hormones, and neurotransmitters. RSKs function in the regulation of cell cycle progression, cell differentiation, and cell survival. RSK2 is necessary for epidermal growth factor (EGF)-mediated phosphorylation of histone H3, a key step in the mitogenic response of mammalian cells. RSK2 is activated by phosphorylation at S227, S369 and T577. Phosphorylation at Y529 induces interaction with ERK1and ERK2, as well as FGFR3. RSK2 forms a complex with either ERK1 or ERK2 in quiescent cells. RSK2 has been shown to mediate growth factor signalling via Ras and MAPK leading to the induction of CREB S133 phosphorylation and activation. Mutations in RSK2 have been shown to be responsible for Coffin-Lowry syndrome (CLS) which is a X-linked disorder characterized by severe psychomotor retardation, facial and digital dysmorphisms, and progressive skeletal deformations. RSK2 has also been linked with the development of breast carcinomas, gastric adenocarcinomas, and glioblastoma multiforme (GM). Insertional mutagenesis studies in mice support a role for this protein kinase in mouse cancer oncogenesis.